File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Deamination of released 3H-noradrenaline in the canine saphenous vein

TitleDeamination of released 3H-noradrenaline in the canine saphenous vein
Authors
Issue Date1982
PublisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00210/index.htm
Citation
Naunyn-Schmiedeberg's Archives Of Pharmacology, 1982, v. 318 n. 3, p. 148-157 How to Cite?
AbstractExperiments were designed to determine the effect of monoamine oxidase (MAO) inhibitors on the release and the metabolism of noradrenaline in the canine saphenous vein. Helical strips were incubated with 3H-noradrenaline and mounted for superfusion and measurement of the efflux of labelled transmitter and its metabolites; in certain experiments the tissue content of 3H-noradrenaline and its metabolites was also determined. The MAO-A inhibitor clorgyline, and the non-specific inhibitor pargyline, but not the MAO-B inhibitor deprenyl decreased the appearance of deaminated and O-methylated deaminated metabolites under basal conditions and during electrical stimulation. The MAO-A and the non-specific MAO inhibitor did not decrease the efflux of VMA to the same extent as that of the other deaminated metabolites. During superfusion with etidocaine, an agent causing increased leakage of stored transmitter, clorgyline abolished the appearance of DOPEG. Addition of semicarbazide in preparations treated with pargyline did not affect the efflux of deaminated and O-methylated deaminated metabolites. From the measurement of tissue VMA, it appeared that the efflux of VMA poorly reflects quick changes in the rate of its formation but that formation is abolished by pretreatment with pargyline. These experiments indicate that in the canine saphenous vein: (1) DOPEG is formed mainly in intraneuronal sites, while DOMA, MOPEG and VMA are formed extraneuronally; (2) VMA is retained in the tissue after its formation; and (3) the only subtype of MAO involved in the metabolism of 3H-noradrenaline released from adrenergic nerve endings can be classified as MAO-A.
Persistent Identifierhttp://hdl.handle.net/10722/170670
ISSN
2015 Impact Factor: 2.376
2015 SCImago Journal Rankings: 0.859
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorVerbeuren, TJen_US
dc.contributor.authorVanhoutte, PMen_US
dc.date.accessioned2012-10-30T06:10:21Z-
dc.date.available2012-10-30T06:10:21Z-
dc.date.issued1982en_US
dc.identifier.citationNaunyn-Schmiedeberg's Archives Of Pharmacology, 1982, v. 318 n. 3, p. 148-157en_US
dc.identifier.issn0028-1298en_US
dc.identifier.urihttp://hdl.handle.net/10722/170670-
dc.description.abstractExperiments were designed to determine the effect of monoamine oxidase (MAO) inhibitors on the release and the metabolism of noradrenaline in the canine saphenous vein. Helical strips were incubated with 3H-noradrenaline and mounted for superfusion and measurement of the efflux of labelled transmitter and its metabolites; in certain experiments the tissue content of 3H-noradrenaline and its metabolites was also determined. The MAO-A inhibitor clorgyline, and the non-specific inhibitor pargyline, but not the MAO-B inhibitor deprenyl decreased the appearance of deaminated and O-methylated deaminated metabolites under basal conditions and during electrical stimulation. The MAO-A and the non-specific MAO inhibitor did not decrease the efflux of VMA to the same extent as that of the other deaminated metabolites. During superfusion with etidocaine, an agent causing increased leakage of stored transmitter, clorgyline abolished the appearance of DOPEG. Addition of semicarbazide in preparations treated with pargyline did not affect the efflux of deaminated and O-methylated deaminated metabolites. From the measurement of tissue VMA, it appeared that the efflux of VMA poorly reflects quick changes in the rate of its formation but that formation is abolished by pretreatment with pargyline. These experiments indicate that in the canine saphenous vein: (1) DOPEG is formed mainly in intraneuronal sites, while DOMA, MOPEG and VMA are formed extraneuronally; (2) VMA is retained in the tissue after its formation; and (3) the only subtype of MAO involved in the metabolism of 3H-noradrenaline released from adrenergic nerve endings can be classified as MAO-A.en_US
dc.languageengen_US
dc.publisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00210/index.htmen_US
dc.relation.ispartofNaunyn-Schmiedeberg's Archives of Pharmacologyen_US
dc.subject.meshAnimalsen_US
dc.subject.meshBiotransformationen_US
dc.subject.meshDeaminationen_US
dc.subject.meshDogsen_US
dc.subject.meshDrug Interactionsen_US
dc.subject.meshElectric Stimulationen_US
dc.subject.meshEtidocaine - Pharmacologyen_US
dc.subject.meshMonoamine Oxidase Inhibitors - Pharmacologyen_US
dc.subject.meshMuscle, Smooth, Vascular - Metabolismen_US
dc.subject.meshNorepinephrine - Metabolismen_US
dc.subject.meshSaphenous Vein - Metabolismen_US
dc.subject.meshTime Factorsen_US
dc.subject.meshVanilmandelic Acid - Metabolismen_US
dc.titleDeamination of released 3H-noradrenaline in the canine saphenous veinen_US
dc.typeArticleen_US
dc.identifier.emailVanhoutte, PM:vanhoutt@hku.hken_US
dc.identifier.authorityVanhoutte, PM=rp00238en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1007/BF00500474-
dc.identifier.pmid7063044-
dc.identifier.scopuseid_2-s2.0-0020003938en_US
dc.identifier.volume318en_US
dc.identifier.issue3en_US
dc.identifier.spage148en_US
dc.identifier.epage157en_US
dc.identifier.isiWOS:A1982NE67200002-
dc.publisher.placeGermanyen_US
dc.identifier.scopusauthoridVerbeuren, TJ=7007006534en_US
dc.identifier.scopusauthoridVanhoutte, PM=7202304247en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats